Figure: 1
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.
Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated much of his career to developing, validating, and optimizing outcome measures to evaluate the efficacy of novel therapeutics in CD and UC.
"We are thrilled to welcome Dr. Feagan to our Clinical Advisory Board," said JD Finley, Chief Executive Officer of Palisade Bio. "Dr. Feagan's extensive research experience in CD and UC, along with his deep expertise in clinical trial design, will be invaluable as we advance the development of our next-generation precision therapies, beginning with PALI-2108 for the treatment of ulcerative colitis."
Dr. Feagan commented, "Patients and clinicians are increasingly seeking oral treatment options that are more effective, safe and well-tolerated. PALI-2108's localized bioactivation holds the potential to address the tolerability issues associated with systemic distribution of this class of therapeutics. I look forward to collaborating with the Company to explore the most effective strategies for demonstrating clinical efficacy and advancing the development of this promising candidate, which targets significant unmet medical needs."
Brian G. Feagan, MD, FRCPC
Dr. Feagan currently serves as a Professor of Medicine at the Schulich School of Medicine & Dentistry at the University of Western Ontario, a gastroenterologist at London Health Sciences Centre in Ontario, Canada, and the Senior Scientific Director of Alimentiv, Inc. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn's and Colitis Canada (CCC) and European Crohn's and Colitis Organization (ECCO). Over the course of his career, he has authored over 480 articles and book chapters and has given over 600 invited presentations at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario and in 2020, he became Senior Scientific Director of Alimentiv Inc. (formerly Robarts Clinical Trials).
Dr. Feagan completed a medical degree at the University of Western Ontario (UWO) in London, Ontario, Canada. His postdoctoral training included a residency in Internal Medicine and a clinical fellowship in Gastroenterology in the Department of Medicine at UWO, and postgraduate training in the Department of Epidemiology and Biostatistics at McMaster University, Hamilton, Ontario.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .
Forward Looking Statements
This communication contains "forward-looking" statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company's ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
Attachment
図: 1
パリセード・バイオがブライアン・フィーガン博士（MD, FRCPC）を臨床諮問委員会に任命
カールスバッド（カリフォルニア州）、2024年12月17日（GLOBE NEWSWIRE） -- パリセード・バイオ社（ナスダック: PALI）（「パリセード」、「パリセード・バイオ」または「当社」）は、自己免疫、炎症、線維症の疾患を持つ患者向けに新しい治療法の開発に焦点を当てた臨床段階のバイオ医薬品企業であり、ブライアン・G・フィーガン博士（MD, FRCPC）を臨床諮問委員会に任命したことを発表しました。
フィーガン博士は、大腸クローン病（CD）および潰瘍性大腸炎（UC）に関する大規模ランダム化対照試験（RCT）の設計、実施、執行に30年以上の経験を持つ著名な消化器科医です。彼は140以上の多施設RCTで主研究者を務めており、CDおよびUCにおける新しい治療法の有効性を評価するための成果指標の開発、検証、最適化に多くのキャリアを捧げてきました。
「フィーガン博士を私たちの臨床諮問委員会に迎えられることを非常に嬉しく思います」と、パリセード・バイオのCEOであるJD・フィンリーは述べました。「CDおよびUCに関するフィーガン博士の豊富な研究経験と臨床試験設計における深い専門知識は、潰瘍性大腸炎の治療に向けてPALI-2108から始まる次世代の精密治療法の開発を進める上で非常に貴重です。」
フィーガン博士は、「患者と臨床医は、より効果的で安全かつ良好に耐えられる経口治療法をますます求めています。PALI-2108の局所的な生体活性化は、このクラスの治療法に伴う耐容性の問題に対処する可能性を秘めています。臨床的な有効性を示し、この有望な候補の開発を進めるための最も効果的な戦略を探るために、会社と協力できることを楽しみにしています。この候補は、重要な未解決の医療ニーズに対応しています。」
ブライアン・G・フィーガン、医学博士、FRCPC
フィーガン博士は現在、オンタリオ州ウェスタンオンタリオ大学のシュリック医学校および歯学部の医学教授、カナダのオンタリオ州ロンドン健康科学センターの消化器専門医であり、Alimentiv, Inc.の上級科学ディレクターを務めています。カナダ王立内科医師会および外科医会のフェローであるフィーガン博士は、カナダおよびアメリカ消化器学会、アメリカ消化器病学会、オンタリオ州内科医師会、クローン病および潰瘍性大腸炎カナダ（CCC）、および欧州クローン病および潰瘍性大腸炎機関（ECCO）を含む団体に加盟しています。キャリアの中で、彼は480以上の論文および書籍の章を著し、全国および国際的な科学会議で600回以上の招待講演を行っています。1997年にフィーガン博士はウェスタンオンタリオ大学のロバータ臨床試験センターのディレクターに就任し、2020年にはAlimentiv Inc.（旧ロバータ臨床試験）の上級科学ディレクターになりました。
フィーガン博士はカナダのオンタリオ州ロンドンにあるウェスタンオンタリオ大学（UWO）で医学の学位を取得しました。彼のポスドク訓練には、UWOの医学部での内科の研修医と消化器内科の臨床フェローシップ、オンタリオ州ハミルトンにあるマクマスター大学の疫学および生物統計学部での大学院後の訓練が含まれています。
About Palisade Bio
パリセードバイオは、自身の免疫疾患、炎症疾患、線維症疾患を抱える患者のために新しい治療法の開発と前進に焦点を当てた臨床段階のバイオ製薬会社です。同社は、独自の治療法でターゲットを絞ったアプローチを使用することで、治療の風景を変革すると信じています。詳細については、こちらをご覧ください。 .
将来に関する記述
This communication contains "forward-looking" statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company's ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-k for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
投資家向け広報連絡先
JTCチーム、LLC
ジェネーン・トーマス
908-824-0775
PALI@jtcir.com
添付ファイル
